All Pharma News
Destiny ends COVID collab, Santhera returns lonodelestat

Destiny ends COVID collab, Santhera returns lonodelestat
James Waldron FIERCE BIOTECH
25 Apr 2024
Share Share
Destiny Pharma & SporeGen® announce update from research collaboration

Destiny Pharma & SporeGen® announce update from research collaboration
PHARMIWEB
02 May 2023
Share Share
UK biotech hands off mid-stage C. difficile drug in up to $570M deal

UK biotech hands off mid-stage C. difficile drug in up to $570M deal
Paul Schloesser ENDPTS
27 Feb 2023
Share Share
Destiny seals C. diff therapy`s phase 3 fate with Sebela

Destiny seals C. diff therapy`s phase 3 fate with Sebela
Annalee Armstrong FIERCE BIOTECH
24 Feb 2023
Share Share
Destiny Pharma targets growth as anti-infection treatments return to prominence

Destiny Pharma targets growth as anti-infection treatments return to prominence
PROACTIVEINVESTORS
18 Nov 2022
Share Share
Destiny Pharma PLC - Study gives strong support for potential of XF-73

Destiny Pharma PLC - Study gives strong support for potential of XF-73
VOXMARKET
18 Oct 2021
Share Share
Destiny Pharma: Expansion of clinical pipeline

Destiny Pharma: Expansion of clinical pipeline
STOCKMARKETWIRE
27 Sep 2021
Share Share
Destiny Pharma & US Department of Veterans Affairs enter into R&D Agreement

Destiny Pharma & US Department of Veterans Affairs enter into R&D Agreement
MARKETSCREENER
06 Jul 2021
Share Share
XF-73 data abstract to be presented at 2021 ECCMID

XF-73 data abstract to be presented at 2021 ECCMID
PRESS RELEASE
10 Jun 2021
Share Share
DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2

DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2
BUSINESSWIRE
06 Apr 2021
Share Share